Data Sheet (Cat.No.TMAZ-0055)

TargetMol

Anti-PD-L1 Monoclonal Antibody

Product Details

Ig Type:	Rabbit monoclonal IgG
Reactivity:	Human
Conjugation:	Unconjugated
Molecular Weight:	150 kDa
Purification:	Protein A Affinity Purified

Applications

Verified Activity:	Flow cytometry analysis of PD-L1 overexpressed 293F cells with TMAZ-0055BI, which was counjucated with SA-PE (red). The WT 293F control is black line.
Application:	ELISA,FCM,IF
Recommended	0.1-0.2 μg/10E6 cells for FCM; 1 ng/μl for ELISA

Properties

Purity:	> 95% as determined by SDS-PAGE.
Stability & Storage:	Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles.
Shipping:	Shipping with blue ice.

Antigen Details

Immunogen:	PD-L1
Antigen Species:	Human
Gene ID:	29126
Uniprot ID:	Q9NZQ7
Synonyms:	Programmed cell death 1 ligand 1;B7 homolog 1
Biology Area:	Immunology Research

Research Background

Plays a critical role in induction and maintenance of immune tolerance to self (PubMed: 11015443, PubMed: 28813410, PubMed: 28813417, PubMed: 31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed: 11015443, PubMed: 28813410, PubMed: 28813417, PubMed: 36727298). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed: 10581077). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed: 32929201)|The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed: 28813410, PubMed: 28813417). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity)

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481